Nanobiotix S.A (NANO)
Euronext Paris · France · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 30.30 |
|---|---|
| 52-week range | 13.10 – 47.66 |
| Return, 1 month / 3 months | +3.9% / −14.0% |
| Return, 1 year / 3 years | +126.8% / +418.8% |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 75.1% |
| Worst drawdown (1 year) | -59.2% |
| Average daily value traded | 5.37M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nanobiotix is a clinical-stage biotechnology company based in Paris, France. It develops nanoparticle-based approaches intended to improve the effectiveness of radiotherapy in cancer treatment. Its main programme uses hafnium oxide nanoparticles, given as an injectable product, to amplify the radiation dose inside tumour cells while sparing surrounding healthy tissue. The company works with hospital clinicians and research partners on studies in several tumour types, and it also pursues oncology programmes built on its nanoparticle platform.
Nanobiotix S.A trades under the code NANO on the Euronext Paris in France, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nanobiotix S.A (NANO) trades on the Euronext Paris in France. It last closed at EUR 30.30 on 27 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 260 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 126.8% and over the last three months it fell 14.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 4.1% | ||
| From 52-week high | -34.4% | ||
| Momentum | 72 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -14.0% | ||
| 6-month return | 6.8% | ||
| 12-month return, skipping the last month | 118.3% | ||
| Stability (higher is calmer) | 19 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 75.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -59.2% | ||
| Liquidity | 88 · Strong | Trades actively. | |
| Average daily value traded | 5.37M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +42.9% |
|---|---|
| 1 month | +3.9% |
| 3 months | −14.0% |
| 6 months | +6.8% |
| 1 year | +126.8% |
| 3 years | +418.8% |
| 5 years | +216.6% |
Signals
| 50-day / 200-day average | 28.72 / 29.09 |
|---|---|
| Golden / death cross (60 days) | Death, 2 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.12 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.